Dr. Rubino currently serves as the Executive in Residence at Stellanova. He is the Chief Executive Officer of Sporos Bioventures and has over 30 years of pharmaceutical and biotechnology company experience in the areas of business development & licensing, marketing, commercial operations, and strategic planning across a wide range of therapeutic areas. Dr. Rubino has extensive experience developing and commercializing oncology products both in the US and EU. He is currently a member of the Board of Directors of Viracta, and prior to joining Sporos as CEO, Dr. Rubino served as the Chief Business Officer at Celyad Oncology SA and was a member of the Board of Directors of Sermonix Pharmaceuticals. Previously, he was the Chief Business & Strategy Officer at Omega Therapeutics and Global Head of Business Development and Licensing and New Product Marketing for the Cell and Gene Therapies business unit at Novartis Pharmaceuticals. Dr. Rubino received his Ph.D. in virology from Cornell University and an MBA from Baruch College.
Harold Levy is the co-founder of Iridian Asset Management, which came to fruition in 1996. Previously, Harold worked as a portfolio manager with Arnhold and S. Bleichroeder, Inc. and served as a research analyst with Lehman Brothers Kuhn Loeb and E.M. Warburg, Pincus & Company. Harold holds a BA in economics from Wesleyan University and an M.B.A. from University of Chicago.